Analysis covariate | Comparison | OR (95% CI) | p Value |
---|---|---|---|
Population: complete population (n=370) | |||
TF | |||
Anti-dsDNA at baseline | Positive (≥30) vs negative (<30) | 12.7 (1.6 to 101) | 0.0167 |
UP/C reduction by week 8 | No 25% reduction vs 25% reduction | 2.6 (1.5 to 4.4) | 0.0006 |
Anti-dsDNA reduction by week 8 | No reduction vs reduction | 2.9 (1.5 to 5.4) | 0.0012 |
C3 normalisation by week 8 | No normalisation vs normalisation | 1.7 (0.9 to 3.1) | 0.0766 |
Complete renal remission | |||
Ethnicity | Non-Hispanic vs Hispanic | 2.0 (1.2 to 3.3) | 0.0061 |
C4 normalisation by week 8 | No normalisation vs normalisation | 0.6 (0.4 to 1.1) | 0.0794 |
Population: maintenance population (n=227) | |||
TF | |||
Induction treatment | IVC vs MMF | 0.5 (0.2 to 1.0) | 0.0500 |
Antimalarial treatment | No treatment vs treatment | 2.4 (1.1 to 5.1) | 0.0209 |
UP/C reduction by week 8 | No 25% reduction vs 25% reduction | 2.1 (1.0 to 4.2) | 0.0471 |
Anti-dsDNA reduction by week 8 | No reduction vs reduction | 3.5 (1.4 to 9.2) | 0.0097 |
Anti-dsDNA at end of induction | Positive (≥30) vs negative (<30) | 8.3 (1.0 to 66.0) | 0.0464 |
Complete renal remission | |||
Age group* | >20 and ≤30 vs ≤20 | 0.7 (0.3 to 1.8) | 0.4801 |
>30 and ≤40 vs ≤20 | 1.8 (0.7 to 4.5) | 0.2303 | |
>40 vs ≤20 | 2.7 (0.9 to 8.3) | 0.0804 | |
eGFR at baseline | ≥90 vs <90 | 2.0 (1.0 to 3.8) | 0.0407 |
UP/C at end induction | >1 vs ≤1 | 0.3 (0.2 to 0.6) | 0.0008 |
TF: ORs >1 imply more failure in first factor level of comparison.
Complete renal remission: ORs >1 imply more remission in first factor level of comparison.
C3 (mg/dL) normalisation: change from <90 at baseline to ≥90 at week 8.
C4 (mg/dL) normalisation: change from <16 at baseline to ≥16 at week 8.
Anti-dsDNA (IU/mL) reduction: >200 at baseline to ≤60 at week 8.
>30 and ≤200 at baseline to ≤30 at week 8.
*Overall p value for age: p=0.0279.
Anti-dsDNA, anti-double-stranded DNA; eGFR, estimated glomerular filtration rate; IVC, intravenous cyclophosphamide; MMF, mycophenolate mofetil; TF, treatment failure; UP/C, urine protein:creatinine ratio.